Industry · Health Care · close of 4 Nov 2026
Pharmaceutical Stocks
119 NSE-listed pharmaceutical companies, largest first, with each one's stage, price and valuation after the close.
119
companies
53 (45%)
in a Stage 2 uptrend
+1.8%
3-month return, weighted by size
3 · 33 · 26
in Stage 1 · 3 · 4
Only the Stage 2 ones →Filter them in the screener →All Health Care stocks →Industry rotation →
Every pharmaceutical stock we track
| Stock | Stage | Close | Day | 3 months | From high | RS | P/E | Yield | Market cap |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | Stage 3, wk 5 | ₹1,773.40 | +0.2% | -9.7% | -11.4% | 72 | 39.1 | 0.90% | ₹4.25L Cr |
| TORNTPHARMTorrent Pharmaceuticals | Stage 3, wk 4 | ₹4,738.50 | +1.9% | -5.8% | -7.5% | 85 | 78.4 | 0.82% | ₹1.80L Cr |
| LAURUSLABSLaurus Labs | Stage 2, wk 28 | ₹2,323.80 | 0.0% | +25.6% | -3.4% | 97 | 93.0 | 0.05% | ₹1.26L Cr |
| ZYDUSLIFEZydus Lifesciences | Stage 2, wk 22 | ₹1,188.10 | -4.2% | +5.1% | -4.6% | 80 | 28.2 | 0.08% | ₹1.19L Cr |
| DRREDDYDr Reddy's Laboratories | Stage 1, wk 3 | ₹1,374.00 | +0.4% | +17.2% | -0.1% | 73 | 40.0 | 0.58% | ₹1.14L Cr |
| CIPLACipla | Stage 3, wk 7 | ₹1,402.00 | +0.4% | -4.0% | -11.3% | 56 | 39.0 | 0.93% | ₹1.13L Cr |
| MANKINDMankind Pharma | Stage 3, wk 8 | ₹2,537.90 | +2.5% | +4.1% | -3.1% | 72 | 46.2 | — | ₹1.05L Cr |
| AUROPHARMAAurobindo Pharma | Stage 2, wk 33 | ₹1,705.00 | +0.6% | +7.5% | -1.7% | 91 | 26.5 | — | ₹98,102 Cr |
| LUPINLupin | Stage 4, wk 6 | ₹2,008.60 | -0.4% | -16.7% | -20.1% | 71 | 17.0 | 0.88% | ₹91,851 Cr |
| GLENMARKGlenmark Pharmaceuticals | Stage 2, wk 10 | ₹2,504.70 | +4.0% | +12.6% | -0.4% | 87 | 37.8 | 0.10% | ₹70,689 Cr |
| ALKEMAlkem Laboratories | Stage 4, wk 8 | ₹5,216.50 | -0.4% | -7.0% | -10.7% | 65 | 29.0 | 1.01% | ₹62,371 Cr |
| ABBOTINDIAAbbott India | Stage 4, wk 4 | ₹27,120.00 | +5.1% | -2.5% | -8.1% | 61 | 34.0 | 2.54% | ₹57,628 Cr |
| GLANDGland Pharma | Stage 2, wk 23 | ₹3,159.00 | 0.0% | +22.3% | 0.0% | 93 | 46.1 | 0.63% | ₹52,127 Cr |
| IPCALABIPCA Laboratories | Stage 2, wk 43 | ₹1,972.00 | +1.1% | +16.4% | -1.9% | 90 | 38.2 | 0.30% | ₹50,030 Cr |
| GLAXOGlaxoSmithKline Pharmaceuticals | Stage 3, wk 1 | ₹2,531.80 | -1.7% | -4.4% | -18.5% | 63 | 40.8 | 2.21% | ₹42,890 Cr |
| AJANTPHARMAjanta Pharma | Stage 3, wk 2 | ₹3,316.70 | -0.1% | -5.9% | -10.8% | 87 | 32.9 | 1.81% | ₹41,445 Cr |
| EMCUREEmcure Pharmaceuticals | Stage 3, wk 2 | ₹2,160.40 | +9.3% | +9.2% | 0.0% | 92 | 37.0 | 0.18% | ₹40,985 Cr |
| PPLPHARMAPiramal Pharma | Stage 2, wk 16 | ₹237.76 | +1.7% | +17.4% | -0.9% | 79 | — | — | ₹31,529 Cr |
| WOCKPHARMAWockhardt | Stage 2, wk 8 | ₹1,899.00 | +1.7% | -6.1% | -18.5% | 89 | 76.1 | — | ₹30,861 Cr |
| RUBICONRubicon Research | Stage 3, wk 1 | ₹1,716.80 | -0.1% | +13.2% | -7.7% | 98 | 98.5 | 0.09% | ₹28,420 Cr |
| NEULANDLABNeuland Laboratories | Stage 3, wk 1 | ₹19,576.00 | +0.8% | +1.6% | -18.4% | 82 | 50.3 | 0.17% | ₹25,116 Cr |
| GRANULESGranules India | Stage 3, wk 4 | ₹794.60 | -0.4% | -3.8% | -12.6% | 87 | 27.7 | 0.22% | ₹21,675 Cr |
| ALIVUSAlivus Life Sciences | Stage 2, wk 29 | ₹1,520.70 | +2.7% | +13.8% | 0.0% | 93 | 27.2 | 0.34% | ₹18,700 Cr |
| CAPLIPOINTCaplin Point Laboratories | Stage 3, wk 2 | ₹2,416.10 | +2.2% | -6.1% | -15.7% | 80 | 27.1 | 0.34% | ₹18,365 Cr |
| SHILPAMEDShilpa Medicare | Stage 2, wk 26 | ₹931.10 | -0.1% | +44.4% | -13.3% | 97 | 64.1 | 0.07% | ₹18,211 Cr |
| APLLTDAlembic Pharmaceuticals | Stage 3, wk 2 | ₹906.70 | +12.9% | +12.0% | -5.6% | 68 | 22.8 | 1.49% | ₹17,822 Cr |
| PFIZERPfizer | Stage 4, wk 7 | ₹3,834.70 | +0.3% | -21.1% | -27.9% | 33 | 24.2 | 1.93% | ₹17,543 Cr |
| COHANCECohance Lifesciences | Stage 2, wk 11 | ₹450.45 | +2.3% | +6.0% | -42.7% | 9 | 161.3 | — | ₹17,234 Cr |
| ERISEris Lifesciences | Stage 4, wk 10 | ₹1,215.00 | +3.2% | -11.5% | -28.6% | 36 | 22.9 | 0.61% | ₹16,857 Cr |
| ASTRAZENAstrazeneca Pharma India | Stage 4, wk 15 | ₹6,368.00 | +0.4% | -22.4% | -35.2% | 27 | 93.5 | 0.57% | ₹15,920 Cr |
| NATCOPHARMNatco Pharma | Stage 4, wk 13 | ₹788.75 | +0.9% | -14.0% | -34.6% | 64 | 12.5 | 0.56% | ₹15,473 Cr |
| JUBLPHARMAJubilant Pharmova | Stage 2, wk 5 | ₹939.55 | +0.1% | +0.7% | -20.5% | 49 | 42.5 | 0.53% | ₹14,883 Cr |
| MARKSANSMarksans Pharma | Stage 2, wk 24 | ₹301.65 | -4.3% | +12.1% | -13.2% | 92 | 27.9 | 0.28% | ₹13,670 Cr |
| SUDEEPPHRMSudeep Pharma | Stage 2, wk 7 | ₹1,116.70 | +1.6% | +28.1% | — | — | 65.5 | 0.14% | ₹12,613 Cr |
| AKUMSAkums Drugs and Pharmaceuticals | Stage 2, wk 29 | ₹751.50 | -1.3% | +12.6% | -8.7% | 92 | 32.0 | 0.39% | ₹11,506 Cr |
| VIYASHViyash Scientific | — | ₹228.46 | +4.1% | -14.2% | — | — | 55.0 | — | ₹10,083 Cr |
| PGHLProcter & Gamble Health | Stage 4, wk 3 | ₹5,738.00 | -2.1% | -11.5% | -17.1% | 63 | 27.7 | 3.53% | ₹9,525 Cr |
| STARStrides Pharma Science | Stage 2, wk 6 | ₹1,014.20 | -2.2% | +2.0% | -17.7% | 82 | 15.4 | 0.49% | ₹9,348 Cr |
| BLUEJETBlue Jet Healthcare | Stage 3, wk 5 | ₹531.85 | +7.1% | -8.6% | -21.1% | 48 | 36.6 | 0.24% | ₹9,226 Cr |
| SANOFICONRSanofi Consumer Healthcare India | Stage 4, wk 9 | ₹3,472.60 | -0.7% | -23.3% | -30.9% | 36 | 28.6 | 2.16% | ₹8,009 Cr |
| SANOFISanofi India | Stage 4, wk 8 | ₹3,450.80 | +2.0% | +1.7% | -27.1% | 35 | 21.4 | 3.63% | ₹7,947 Cr |
| SUVENSuven Life Sciences | Stage 3, wk 4 | ₹276.10 | +5.7% | -10.9% | -29.6% | 88 | — | — | ₹7,802 Cr |
| ENTEROEntero Healthcare Solutions | Stage 2, wk 12 | ₹1,665.00 | +5.3% | +35.2% | -12.3% | 90 | 54.9 | — | ₹7,254 Cr |
| SUPRIYASupriya Lifescience | Stage 2, wk 5 | ₹859.90 | +3.3% | -3.1% | -18.3% | 78 | 34.5 | 0.12% | ₹6,921 Cr |
| CONCORDBIOConcord Biotech | Stage 3, wk 2 | ₹655.50 | +6.8% | -7.7% | -17.4% | 60 | 46.0 | 0.61% | ₹6,858 Cr |
| BLISSGVSBliss GVS Pharma | Stage 2, wk 48 | ₹619.55 | -1.9% | +26.5% | -16.0% | 99 | 42.5 | 0.24% | ₹6,591 Cr |
| FDCF D C | Stage 4, wk 8 | ₹390.95 | +0.6% | -2.9% | -14.0% | 59 | 20.2 | 1.29% | ₹6,365 Cr |
| SPARCSun Pharma Advanced Research Co | Stage 3, wk 10 | ₹185.33 | +5.5% | -10.6% | -33.2% | 84 | 3.6 | — | ₹6,014 Cr |
| INNOVACAPInnova Captab | Stage 2, wk 22 | ₹1,035.00 | +3.2% | +9.9% | -20.2% | 83 | 37.0 | 0.20% | ₹5,923 Cr |
| MOREPENLABMorepen Laboratories | Stage 2, wk 20 | ₹101.33 | -1.0% | +46.5% | -31.1% | 96 | 28.3 | 0.21% | ₹5,552 Cr |
| SENORESSenores Pharmaceuticals | Stage 3, wk 4 | ₹1,137.00 | -0.9% | -16.4% | -26.7% | 89 | 37.5 | — | ₹5,236 Cr |
| GUJTHEMGujarat Themis Biosyn | Stage 2, wk 8 | ₹387.75 | +2.8% | +9.6% | -17.0% | 50 | 84.3 | 0.18% | ₹5,047 Cr |
| SMSPHARMASMS Pharmaceuticals | Stage 2, wk 6 | ₹525.50 | +2.2% | +44.6% | 0.0% | 94 | 44.8 | 0.08% | ₹4,921 Cr |
| ORCHPHARMAOrchid Pharma | Stage 3, wk 3 | ₹876.75 | +4.0% | -12.9% | -20.8% | 82 | 532.8 | — | ₹4,447 Cr |
| GUFICBIOGufic Biosciences | Stage 2, wk 18 | ₹428.90 | +3.0% | +8.0% | -4.3% | 83 | 56.7 | 0.02% | ₹4,301 Cr |
| RPGLIFERPG Life Sciences | Stage 2, wk 19 | ₹2,598.50 | +2.7% | -5.4% | -15.9% | 75 | 38.1 | 0.93% | ₹4,298 Cr |
| ZOTAZota Health Care | Stage 1, wk 3 | ₹1,217.90 | -1.2% | -2.8% | -27.8% | 40 | — | 0.08% | ₹4,218 Cr |
| JSLLJeena Sikho Lifecare | Stage 4, wk 19 | ₹336.65 | -2.1% | -41.4% | -57.6% | 5 | 18.0 | 1.31% | ₹4,185 Cr |
| AARTIDRUGSAarti Drugs | Stage 3, wk 2 | ₹455.80 | -2.3% | +10.1% | -12.0% | 61 | 22.3 | 0.43% | ₹4,160 Cr |
| KPLKwality Pharmaceuticals | Stage 2, wk 43 | ₹3,741.00 | +3.0% | +44.6% | -2.6% | 99 | 46.1 | — | ₹3,882 Cr |
| UNICHEMLABUnichem Laboratories | Stage 3, wk 4 | ₹505.45 | +0.4% | +1.0% | -22.3% | 74 | 12.0 | — | ₹3,559 Cr |
| SHUKRAPHARShukra Pharmaceuticals | — | ₹79.87 | 0.0% | — | — | — | 103.4 | 0.01% | ₹3,534 Cr |
| INDSWFTLABIND Swift Laboratories | Stage 2, wk 21 | ₹370.55 | +7.8% | +61.0% | -10.3% | 99 | 36.7 | — | ₹3,274 Cr |
| SOLARASolara Active Pharma Sciences | Stage 2, wk 9 | ₹644.90 | +2.4% | +23.9% | -14.3% | 75 | 82.2 | — | ₹3,112 Cr |
| HIKALHikal | Stage 3, wk 4 | ₹222.63 | +3.8% | -2.6% | -13.0% | 60 | — | 0.28% | ₹2,745 Cr |
| FREDUNFredun Pharmaceuticals | Stage 2, wk 31 | ₹1,508.70 | +3.7% | +35.9% | -2.8% | 98 | 52.8 | — | ₹2,577 Cr |
| ALEMBICLTDAlembic | Stage 2, wk 8 | ₹94.71 | +6.0% | +7.0% | -15.0% | 64 | 7.2 | 2.69% | ₹2,432 Cr |
| SAKARSakar Healthcare | Stage 2, wk 54 | ₹979.50 | +3.7% | +6.9% | -17.6% | 98 | 68.4 | — | ₹2,150 Cr |
| SAIPARENTSai Parenterals | — | ₹478.50 | +2.0% | -10.0% | — | — | 161.7 | — | ₹2,114 Cr |
| INDOCOIndoco Remedies | Stage 2, wk 14 | ₹213.43 | -0.8% | -4.5% | -23.9% | 41 | 62.4 | 0.09% | ₹1,968 Cr |
| SYNCOMFSyncom Formulations (India) | Stage 2, wk 10 | ₹20.56 | +7.8% | +54.6% | -21.5% | 82 | 21.2 | 0.50% | ₹1,933 Cr |
| VENUSREMVenus Remedies | Stage 3, wk 8 | ₹1,380.90 | +5.0% | -11.1% | -29.1% | 98 | 14.7 | 0.75% | ₹1,848 Cr |
| WINDLASWindlas Biotech | Stage 2, wk 16 | ₹873.45 | -0.7% | +1.3% | -24.4% | 62 | 27.1 | 0.72% | ₹1,802 Cr |
| BETABeta Drugs | Stage 3, wk 6 | ₹1,769.60 | +2.9% | -25.2% | -33.7% | 62 | 25.3 | — | ₹1,794 Cr |
| NGLFINENgl Fine Chem | Stage 3, wk 8 | ₹2,653.20 | +3.6% | -18.6% | -23.3% | 94 | 27.6 | 0.07% | ₹1,639 Cr |
| AMRUTANJANAmrutanjan Health Care | Stage 4, wk 16 | ₹513.30 | +3.0% | -0.9% | -30.6% | 29 | 26.7 | 0.98% | ₹1,483 Cr |
| JAGSNPHARMJagsonpal Pharmaceuticals | Stage 3, wk 2 | ₹221.57 | +2.5% | -6.3% | -9.2% | 68 | 32.8 | 1.83% | ₹1,464 Cr |
| AHCLAnlon Healthcare | Stage 2, wk 19 | ₹26.66 | +5.0% | +83.0% | -26.7% | 96 | 47.9 | — | ₹1,417 Cr |
| TTKHLTCARETTK Healthcare | Stage 3, wk 2 | ₹927.50 | +1.3% | -10.6% | -22.1% | 42 | 4.7 | 1.09% | ₹1,311 Cr |
| FERMENTAFermenta Biotech | Stage 3, wk 1 | ₹439.80 | +2.8% | -19.0% | -22.8% | 92 | 20.7 | — | ₹1,263 Cr |
| BPLPHARMABharat Parenterals | Stage 2, wk 22 | ₹1,800.60 | -4.9% | +25.0% | -16.2% | 88 | — | 0.05% | ₹1,241 Cr |
| KOPRANKopran | Stage 2, wk 22 | ₹249.45 | +1.3% | +31.9% | -14.2% | 90 | 46.2 | 1.26% | ₹1,205 Cr |
| BAJAJHCAREBajaj Healthcare | Stage 4, wk 6 | ₹308.60 | +0.8% | -8.0% | -35.8% | 27 | 41.9 | 0.49% | ₹1,039 Cr |
| BAFNAPHBafna Pharmaceuticals | Stage 2, wk 21 | ₹438.80 | +2.0% | +60.4% | -6.7% | 98 | 130.8 | — | ₹1,038 Cr |
| LINCOLNLincoln Pharmaceuticals | Stage 4, wk 2 | ₹510.35 | +1.2% | -14.0% | -32.7% | 65 | 10.4 | 0.36% | ₹1,022 Cr |
| THEMISMEDThemis Medicare | Stage 3, wk 2 | ₹99.52 | -0.2% | -13.8% | -25.2% | 40 | 22.9 | 0.50% | ₹924 Cr |
| ONEGLOBALOne Global Service Provider | Stage 4, wk 8 | ₹439.70 | -1.1% | -16.6% | -43.8% | 84 | 12.1 | 0.22% | ₹859 Cr |
| SGRLShree Ganesh Remedies | Stage 2, wk 6 | ₹652.20 | +4.5% | +4.8% | -11.3% | 85 | 52.8 | — | ₹837 Cr |
| ANUHPHRAnuh Pharma | Stage 2, wk 12 | ₹82.86 | +2.1% | +3.1% | -14.3% | 59 | 18.4 | 1.85% | ₹830 Cr |
| KILITCHKilitch Drugs (India) | Stage 2, wk 6 | ₹208.91 | +3.4% | +9.8% | -19.9% | 71 | 23.0 | — | ₹730 Cr |
| ZIMLABZIM Laboratories | Stage 2, wk 25 | ₹134.43 | -5.6% | +23.3% | -11.9% | 95 | 170.5 | — | ₹720 Cr |
| AMANTAAmanta Healthcare | Stage 2, wk 17 | ₹184.91 | +7.2% | +8.9% | -10.7% | 89 | 41.5 | — | ₹718 Cr |
| WANBURYWanbury | Stage 4, wk 5 | ₹192.41 | +0.4% | -31.0% | -44.2% | 37 | 11.8 | — | ₹673 Cr |
| VALIANTLABValiant Laboratories | Stage 2, wk 10 | ₹120.87 | -2.0% | +94.4% | -14.1% | 88 | 43.0 | — | ₹656 Cr |
| FABTECHFabtech Technologies | Stage 4, wk 14 | ₹132.30 | +2.3% | -12.7% | -47.4% | 9 | 10.5 | 0.46% | ₹588 Cr |
| ALBERTDAVDAlbert David | Stage 2, wk 10 | ₹768.95 | 0.0% | +10.7% | -14.4% | 59 | 19.5 | 0.65% | ₹439 Cr |
| HALEOSLABSHaleos Labs | Stage 2, wk 2 | ₹1,398.60 | +0.1% | -12.0% | — | — | 25.9 | 0.11% | ₹423 Cr |
| JENBURPHJenburkt Pharmaceuticals | Stage 4, wk 10 | ₹936.25 | +4.7% | -13.1% | -25.1% | 54 | 12.5 | 2.23% | ₹413 Cr |
| MEDICAMEQMedicamen Biotech | Stage 2, wk 3 | ₹263.15 | +0.4% | +4.9% | -36.7% | 36 | 34.7 | 0.39% | ₹370 Cr |
| AAREYDRUGSAarey Drugs and Pharmaceuticals | Stage 2, wk 10 | ₹109.29 | +3.3% | +30.3% | -4.0% | 82 | 71.9 | — | ₹348 Cr |
| NURECANureca | Stage 3, wk 1 | ₹307.50 | +0.8% | -5.7% | -16.1% | 74 | 61.8 | — | ₹307 Cr |
| LYKALABSLyka Labs | Stage 2, wk 10 | ₹75.57 | 0.0% | +13.4% | -20.6% | 45 | — | — | ₹273 Cr |
| NECLIFENectar Lifesciences | Stage 4, wk 1 | ₹10.26 | +1.2% | -2.6% | -53.9% | 27 | 29.1 | — | ₹199 Cr |
| MEDICOMedico Remedies | Stage 4, wk 16 | ₹18.56 | -1.2% | -62.2% | -65.8% | 3 | 11.6 | — | ₹154 Cr |
| NATCAPSUQNatural Capsules | Stage 3, wk 1 | ₹137.78 | +1.8% | -9.7% | -39.3% | 20 | — | — | ₹143 Cr |
| PARPar Drugs and Chemicals | Stage 2, wk 12 | ₹107.90 | -4.7% | +8.8% | -35.9% | 73 | 10.4 | — | ₹133 Cr |
| BALPHARMABal Pharma | Stage 2, wk 8 | ₹82.15 | +0.4% | -6.5% | -28.2% | 68 | 18.0 | 1.47% | ₹131 Cr |
| MAKERSLMakers Laboratories | Stage 2, wk 11 | ₹215.10 | +6.5% | +33.8% | -2.6% | 92 | 35.7 | — | ₹127 Cr |
| KREBSBIOKrebs Biochemicals and Industries | Stage 1, wk 5 | ₹57.10 | +2.1% | +5.2% | -19.9% | 45 | — | — | ₹123 Cr |
| PARNAXLABParnax Lab | Stage 4, wk 6 | ₹104.47 | +0.7% | -21.8% | -36.7% | 44 | 12.8 | — | ₹120 Cr |
| ALPAAlpa Laboratories | Stage 4, wk 13 | ₹54.10 | +4.4% | -19.4% | -41.2% | 17 | 30.8 | — | ₹114 Cr |
| VAISHALIVaishali Pharma | Stage 3, wk 2 | ₹6.73 | -0.9% | -13.9% | -34.0% | 24 | 119.0 | — | ₹88 Cr |
| SUNLOCSunil Healthcare | Stage 3, wk 2 | ₹61.73 | -3.5% | -12.9% | -23.6% | 51 | 20.2 | — | ₹63 Cr |
| AJOONIAjooni Biotech | Stage 4, wk 27 | ₹2.88 | +0.3% | -26.5% | -44.6% | 12 | 11.5 | — | ₹50 Cr |
| BIOFILCHEMBiofil Chemicals and Pharmaceuticals | Stage 4, wk 12 | ₹29.23 | +0.8% | -11.2% | -36.9% | 36 | 170.6 | — | ₹48 Cr |
| MANGALAMMangalam Drugs and Organics | Stage 2, wk 1 | ₹29.73 | +1.9% | +10.2% | -55.6% | 6 | — | — | ₹47 Cr |
| ORTINGLOBEOrtin Global | Stage 4, wk 3 | ₹13.80 | +5.8% | -9.6% | -30.7% | 81 | — | — | ₹11 Cr |
| CORONACorona Remedies | Stage 3, wk 2 | ₹2,405.80 | +5.9% | +11.4% | — | — | 67.1 | 0.44% | — |
| SYMBIOTECSymbiotec Pharmalab | — | ₹1,233.20 | -2.4% | — | — | — | 86.6 | — | — |
Pharmaceutical Stocks: quick answers
How many pharmaceutical stocks are in an uptrend?
As of 4 Nov 2026, 53 of the 119 NSE-listed pharmaceutical stocks we track are in Stage 2, the uptrend phase, including Laurus Labs (LAURUSLABS), Zydus Lifesciences (ZYDUSLIFE), Aurobindo Pharma (AUROPHARMA), Glenmark Pharmaceuticals (GLENMARK) and Gland Pharma (GLAND).
What is the largest pharmaceutical stock?
Sun Pharmaceutical Industries (SUNPHARMA), with a market value of ₹4.25L Cr. It closed at ₹1,773.40 on 4 Nov 2026, in Stage 3.
Which pharmaceutical stocks are near their 52-week high?
As of 4 Nov 2026, 6 are within 5% of a 52-week high: Laurus Labs (LAURUSLABS), Zydus Lifesciences (ZYDUSLIFE), Dr Reddy's Laboratories (DRREDDY), Mankind Pharma (MANKIND), Aurobindo Pharma (AUROPHARMA) and Glenmark Pharmaceuticals (GLENMARK).